ATYR

ATYR

USD

aTyr Pharma Inc. Common Stock

$5.395-0.155 (-2.793%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$5.550

最高

$5.749

最低

$5.330

交易量

2.00M

公司基本面

市值

480.2M

行業

生物科技

國家

United States

交易統計

平均交易量

1.63M

交易所

NCM

貨幣

USD

52週範圍

最低 $1.42當前 $5.395最高 $5.98

相關新聞

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

查看更多
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
GlobeNewswire

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well

查看更多
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world

查看更多
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

查看更多
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
GlobeNewswire

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from

查看更多
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)